Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3558994 | 0.82 | L3MBTL1 (0.52) | RORCCYP3A4GRM5L3MBTL1TYK2 | |
| SCHEMBL25209850 | 0.82 | LMNA (0.45) | RORCLMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3456534 | 0.81 | EGLN2 (0.47) | RORCCYP3A4GRM5 | |
| SCHEMBL15205400 | 0.80 | GRM5 (0.44) | RORCGRM5BRAFUSP30TYK2 | |
| SCHEMBL1490730 | 0.79 | GCK (0.54) | RORCGRM5BRAFUSP30TYK2 | |
| SCHEMBL2035487 | 0.79 | LMNA (0.68) | LMNACYP1A2CYP2C19 | |
| SCHEMBL18785787 | 0.79 | LMNA (0.53) | LMNACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL856063 | 0.78 | MEN1 (0.53) | L3MBTL1USP30 | |
| SCHEMBL19151107 | 0.78 | TYK2 (0.50) | RORCLMNAGRM5BRAFADORA1 | |
| SCHEMBL209579 | 0.78 | LMNA (0.49) | RORCLMNACYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2023-02-09 | — | — | US | disclosed |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043970-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | RORC 1182/4885LMNA 1523/4885CYP1A2 1481/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | RORC 1182/4885LMNA 1523/4885CYP1A2 1481/4885 |
| US-11208388-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | RORC 1182/4885LMNA 1523/4885CYP1A2 1481/4885 |
| US-20180072688-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | RORC 1182/4885LMNA 1523/4885CYP1A2 1481/4885 |
| US-20200172495-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | RORC 1182/4885LMNA 1523/4885CYP1A2 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.